Hims & Hers surges on deal with Eli Lilly to sell obesity drugs
FROM THE WIRE · FINANCE.YAHOO.COM
Hims & Hers Health inked a deal with Eli Lilly on Friday to sell the company's obesity drugs, further entrenching itself in the GLP-1 space. Continue Reading
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishA deal with a major pharma company in the GLP-1 space can move the Hims & Hers stock.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Hims & Hers Health signed a deal with Eli Lilly on Friday.
- 02The agreement covers selling the company's obesity drugs.
- 03The deal further strengthens Hims & Hers in the GLP-1 space.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Hims & Hers Health, Inc.25.14 USD+0.26%today +4.47%Positive Eli Lilly and Company1,363.66 USD+1.39%today -0.08%Neutral
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets